Mucin-binding protein shuttles enable delivery of brain-targeted therapeutics

Read full text Summarise with VIRAT
Authors: Sophia M. Shi, Gabrielle S. Tender, Jian Xiong, Josephine K. Buff, Hannah I. Park, Justin H. Mendiola, Edward N. Wilson, Monther Abu-Remaileh, Carolyn Ruth Bertozzi, Tony Wyss‐Coray
Cited by: 0
References: 37

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

The blood-brain barrier (BBB) poses a major obstacle to the delivery of therapeutics into the central nervous system (CNS) due to its highly restrictive permeability. Here, we introduce glycan-targeted delivery vehicles, or GlycoShuttles, that traverse the BBB by harnessing the cerebrovascular glycocalyx, a carbohydrate-rich layer lining the BBB lumen. We discover that mucin-domain glycoproteins within this structure serve as novel entry portals for brain delivery and engineer mucin-binding protein shuttles that enable efficient transport of diverse molecular cargo across the BBB into multiple key brain cell types. This modular platform facilitates enhanced brain delivery of a variety of payloads, including antibodies and lysosomal proteins, and demonstrates therapeutic efficacy in mouse models of dementia. Our findings establish mucin-targeted GlycoShuttles as a versatile platform for noninvasive brain delivery of therapeutics, opening new avenues for the treatment of CNS diseases.

Fields of Study & Subjects

Barrier Structure and Function Studies Nanoparticle-Based Drug Delivery Drug Transport and Resistance Mechanisms

Publication details

Journal / source
bioRxiv (Cold Spring Harbor Laboratory)
Publication date
25 March 2026
Language
EN
Document type
Preprint